Empirical Finance LLC Has $820,000 Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Empirical Finance LLC lifted its holdings in Illumina, Inc. (NASDAQ:ILMN) by 17.0% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 1,733 shares of the life sciences company’s stock after purchasing an additional 252 shares during the quarter. Empirical Finance LLC’s holdings in Illumina were worth $820,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the stock. BDO Wealth Advisors LLC lifted its stake in Illumina by 90.5% in the 1st quarter. BDO Wealth Advisors LLC now owns 80 shares of the life sciences company’s stock valued at $31,000 after acquiring an additional 38 shares in the last quarter. Evoke Wealth LLC raised its stake in Illumina by 165.6% in the 1st quarter. Evoke Wealth LLC now owns 85 shares of the life sciences company’s stock valued at $33,000 after acquiring an additional 53 shares during the period. Eagle Bay Advisors LLC bought a new stake in Illumina in the 2nd quarter valued at $35,000. Tsfg LLC raised its stake in Illumina by 1,580.0% in the 2nd quarter. Tsfg LLC now owns 84 shares of the life sciences company’s stock valued at $40,000 after acquiring an additional 79 shares during the period. Finally, Meridian Wealth Partners LLC bought a new stake in Illumina in the 1st quarter valued at $41,000. Institutional investors and hedge funds own 88.56% of the company’s stock.

Shares of NASDAQ:ILMN opened at $448.85 on Wednesday. The business has a 50 day simple moving average of $482.60 and a two-hundred day simple moving average of $438.65. The company has a debt-to-equity ratio of 0.32, a current ratio of 6.08 and a quick ratio of 5.64. Illumina, Inc. has a 1 year low of $260.42 and a 1 year high of $555.77. The firm has a market capitalization of $65.85 billion, a PE ratio of 85.99, a price-to-earnings-growth ratio of 2.24 and a beta of 0.91.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, August 5th. The life sciences company reported $1.87 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.36 by $0.51. Illumina had a net margin of 19.36% and a return on equity of 18.12%. The firm had revenue of $1.13 billion during the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter in the previous year, the firm posted $0.62 earnings per share. Equities research analysts expect that Illumina, Inc. will post 6.48 EPS for the current fiscal year.

In related news, SVP Susan H. Tousi sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 4th. The shares were sold at an average price of $500.00, for a total value of $500,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Susan H. Tousi sold 300 shares of the business’s stock in a transaction that occurred on Monday, June 28th. The stock was sold at an average price of $478.95, for a total transaction of $143,685.00. The disclosure for this sale can be found here. Insiders have sold 3,881 shares of company stock valued at $1,873,334 in the last ninety days. Insiders own 0.23% of the company’s stock.

A number of research analysts have commented on the company. SVB Leerink lowered Illumina from an “outperform” rating to a “market perform” rating and set a $425.00 price objective on the stock. in a report on Thursday, August 19th. Robert W. Baird reaffirmed a “hold” rating on shares of Illumina in a research note on Sunday, August 22nd. Barclays raised their price objective on Illumina from $355.00 to $365.00 and gave the company an “underweight” rating in a research note on Friday, August 6th. Zacks Investment Research raised Illumina from a “hold” rating to a “buy” rating and set a $504.00 target price on the stock in a research report on Wednesday, June 30th. Finally, Piper Sandler boosted their target price on Illumina from $510.00 to $560.00 and gave the company an “overweight” rating in a research note on Friday, August 6th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $392.06.

Illumina Profile

Illumina, Inc engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions.

Read More: What is a growth and income fund?

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.